$3.63
▲ +0.0% Today
as of Sep 4, 16:54 ET
Last 30 days
Recent Press Releases & News
Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report?
Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook?
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci
Overview
52-week range
$2.77
$7.18
20% of range
Avg surprise (last 3)
-1.4%
Avg reaction (last 2)
-7.4%
50% positive
Latest IV / EM
91%
EM ±3.8% · $4 · Sep 4
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.25 | — | — | — | — | financials |
| Wed May 6, 2026 | Mar/2026 | $-0.22 | $-0.30 | +26.7% | +56.0% | +1.8% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.36 | — | — | — | — | financials |
| Tue Aug 5, 2025 | Jun/2025 | $-0.41 | $-0.35 | -17.1% | — | — | earnings |
| Mon May 5, 2025 | Mar/2025 | $-0.50 | $-0.44 | -13.6% | — | -16.6% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.34 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.40 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.39 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.43 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.38 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.34 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8M | $6M | — | $5M | $19M | $15M | — | $26M |
| Cost of revenue | $11M | $12M | — | $15M | $20M | $22M | — | $12M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-135M | $-129M | — | $-172M | $-176M | $-191M | — | $-98M |
| Net income | $-131M | $-118M | — | $-162M | $-172M | $-202M | — | $-96M |
| EPS (diluted) | $-0.25 | $-0.22 | — | $-0.36 | $-0.41 | $-0.50 | — | $-0.34 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $546M | $654M | $743M | $660M | $525M | $500M | $594M | $428M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $603M | $710M | $813M | $714M | $587M | $584M | $714M | $474M |
| Total assets | $1.21B | $1.34B | $1.47B | $1.40B | $1.30B | $1.31B | $1.45B | $726M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $298M | $315M | $343M | $353M | $383M | $371M | $414M | $202M |
| Total equity | $915M | $1.02B | $1.13B | $1.05B | $919M | $934M | $1.03B | $525M |